T. Sukigara

MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial

Toshio Shimizu, K. Yonemori, Y. Fujiwara, 2020, Clinical pharmacology and therapeutics.

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.

Y. Hosomi, Y. Ohe, M. Satouchi, 2019, European journal of cancer.

A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.

Teruhiko Yoshida, A. Shimomura, K. Yonemori, 2019, European journal of cancer.

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression

H. Iwata, Y. Fujiwara, Kenichi Inoue, 2014, Breast Cancer Research and Treatment.

MASTER KEY project: A basket/umbrella trial for rare cancers in Japan.

K. Yonemori, T. Shibata, A. Kawai, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

251PEfficacy and safety of olaparib combined with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: The final analysis of a Japanese phase I/II trial

K. Yonemori, N. Masuda, K. Aogi, 2017 .